This report is focused on newer drugs and innovations in chemical compounds, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control, drugs used for symptomatic treatment and not for the elimination of the virus from the host and details on manufacturers and suppliers of non-branded generics. This report will also highlight the current and future market potential of antibiotics with detailed analysis of the competitive environment. Drivers, restraints, opportunities, pricing analysis, impact of COVID-19, other infectious diseases and a regulatory scenario assessment are covered, along with a market projection for 2027 and market share assessment for key players.
The report segments the market for antibiotics based on product type, route of administration, application and geographical region. Based on product type, the market is segmented into cell wall inhibitors, protein inhibitors, DNA and other inhibitors (RNA, mycolic acid, folic acid). Based on route of administration, the market is segmented into oral and topical.
By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, South America and the Middle East and Africa. Detailed analysis of major countries (U.S., Germany, UK, Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa) will be covered in the regional segment. For market estimates, data will be provided for 2021 as the base year, with estimates for 2022 and forecast value for 2027.
Report Includes:
- 22 data tables and 16 additional tables - An overview of the global market for antibiotics within the pharmaceutical industry - Analyses of the global market trends, with data corresponding to market size for 2019-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2027 - Information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace - Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user, and geographical region - Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa - Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances - Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc. and Sanofi
Content Table of Contents
Chapter 1 Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report What's New in This Update? Information Sources Methodology Geographic Breakdown Analyst's Credentials BCC Custom Research Related BCC Research Reports Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background Overview of Antibiotics Common Side Effects of Antibiotics Classification of Antibiotics Cell Wall Inhibitors Protein Inhibitors DNA Inhibitors Other Antibiotic Classes Antibiotic Classification, by Source Overview of Gram-Negative and Gram-Positive Bacteria Route of Administration Trends in the Market for Antibiotics New Antibiotic Development Antibiotic Drug Development, Smaller Pharmaceutical Firms Growing Public/Private Partnerships Chapter 4 Market Dynamics Market Drivers Growth Driven by Antibiotics Rising Elder Population and Infection Rate Increasing Hospital-acquired Infections Improved Awareness Market Restraints Antibiotic-resistant Infections Generics Declining R&D Investment Side Effects of Antibiotics Market Opportunities Market Expansion Novel Antibacterial Agents Chapter 5 Market Breakdown, by Product Global Market for Antibiotics by Product Cell Wall Inhibitors Protein Inhibitors DNA Inhibitors Other Types of Inhibitors Chapter 6 Market Breakdown, by Route of Administration Global Market for Antibiotics by Route of Administration Oral Antibiotics Topical Antibiotics Other Routes of Administration Chapter 7 Market Breakdown, by Region Global Market for Antibiotics by Region North America Europe Asia-Pacific Latin America Middle East and Africa Chapter 8 Impact of COVID-19 on the Pharmaceutical Industry Short-term Impact Change in Demand Shift of Communication and Promotions to Remote Interactions R&D Changes Long-term Impact Delayed Approvals for Non-COVID-related Pharmaceutical Products Self-sufficiency in Pharma Pharmaceutical Industry Growth Slowdown Changes in Consumption Trends in Health-related Products Chapter 9 Clinical Developments and Pipeline Products Respiratory Tract Infections Chapter 10 Value Chain Analysis Introduction China: Center of Microbial Threat Chapter 11 Regulatory Scenario FDA and International Regulation Recent Regulatory Reforms Ketek Case Study Chapter 12 Competitive Landscape Global Company Market Share Analysis Mergers, Collaborations, Partnerships and Acquisitions Chapter 13 Company Profiles ABBOTT F. HOFFMANN-LA ROCHE AG GLAXOSMITHKLINE PLC JOHNSON & JOHNSON MERCK & CO. INC. PFIZER INC. SANOFI VIATRIS INC. Chapter 14 Appendix: Acronyms
List of Tables Summary Table A : Global Market for Antibiotics, by Product, Through 2027 Summary Table B : Global Market for Antibiotics, by Route of Administration, Through 2027 Table 1 : Major Differences, Gram-Positive and Gram-Negative Organisms Table 2 : Proportion of Resistant Strains, by WHO Region Table 3 : Global Market for Antibiotics, by Product, Through 2027 Table 4 : Global Market for Cell Wall Inhibitor, by Product, Through 2027 Table 5 : Global Market for Cell Wall Inhibitors, by Region, Through 2027 Table 6 : Global Market for Protein Inhibitors, by Product, Through 2027 Table 7 : Global Market for Protein Inhibitors, by Region, Through 2025 Table 8 : Global Market for DNA Inhibitors, by Product, Through 2027 Table 9 : Global Market for DNA Inhibitors, by Region, Through 2027 Table 10 : Global Market for Other Types of Inhibitors, by Region, Through 2027 Table 11 : Global Market for Antibiotics, by Route of Administration, Through 2027 Table 12 : Global Market for Antibiotics, by Region, Through 2027 Table 13 : North American Market for Antibiotics, by Product, Through 2027 Table 14 : North American Market for Antibiotics, by Country, Through 2027 Table 15 : European Market for Antibiotics, by Product, Through 2025 Table 16 : European Market for Antibiotics, by Country, Through 2025 Table 17 : Asia-Pacific Market for Antibiotics, by Product, Through 2027 Table 18 : Asia-Pacific Market for Antibiotics, by Country, Through 2027 Table 19 : Latin American Market for Antibiotics, by Product, Through 2027 Table 20 : Latin American Market for Antibiotics, by Country, Through 2025 Table 21 : Middle Eastern and African Market for Antibiotics, by Product, Through 2027 Table 22 : Middle Eastern and African Market for Antibiotics, by Country, Through 2027 Table 23 : Antibiotics and Combinations in Global Clinical Development, Recent Approvals,2023 Table 24 : FDA-approved Antibacterial Drugs, 2018 Table 25 : FDA-Approved Antibacterial Drugs, 2019 Table 26 : Abbott: Antibiotics Product Portfolio Table 27 : F. Hoffmann-La Roche AG: Antibiotics Product Portfolio Table 28 : GlaxoSmithKline Plc: Antibiotics Product Portfolio Table 29 : Johnson & Johnson: Antibiotics Product Portfolio Table 30 : Merck & Co. Inc.: Antibiotics Product Portfolio Table 31 : Merck & Co. Inc.: Antibiotic Drug Overview Table 32 : Pfizer Inc.: Antibiotics Product Portfolio Table 33 : Sanofi: Antibiotics Product Portfolio Table 34 : Sanofi S.A.: Antibiotic Drugs Overview Table 35 : Vitaris Inc.: Antibiotics Product Portfolio Table 36 : Acronyms Used in this Report
This report is focused on newer drugs and innovations in chemical compounds, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control, drugs used for symptomatic treatment and not for the elimination of the virus from the host and details on manufacturers and suppliers of non-branded generics. This report will also highlight the current and future market potential of antibiotics with detailed analysis of the competitive environment. Drivers, restraints, opportunities, pricing analysis, impact of COVID-19, other infectious diseases and a regulatory scenario assessment are covered, along with a market projection for 2027 and market share assessment for key players.
The report segments the market for antibiotics based on product type, route of administration, application and geographical region. Based on product type, the market is segmented into cell wall inhibitors, protein inhibitors, DNA and other inhibitors (RNA, mycolic acid, folic acid). Based on route of administration, the market is segmented into oral and topical.
By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, South America and the Middle East and Africa. Detailed analysis of major countries (U.S., Germany, UK, Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa) will be covered in the regional segment. For market estimates, data will be provided for 2021 as the base year, with estimates for 2022 and forecast value for 2027.
Report Includes:
- 22 data tables and 16 additional tables - An overview of the global market for antibiotics within the pharmaceutical industry - Analyses of the global market trends, with data corresponding to market size for 2019-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2027 - Information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace - Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user, and geographical region - Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa - Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances - Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc. and Sanofi
Table of Contents
Chapter 1 Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report What's New in This Update? Information Sources Methodology Geographic Breakdown Analyst's Credentials BCC Custom Research Related BCC Research Reports Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background Overview of Antibiotics Common Side Effects of Antibiotics Classification of Antibiotics Cell Wall Inhibitors Protein Inhibitors DNA Inhibitors Other Antibiotic Classes Antibiotic Classification, by Source Overview of Gram-Negative and Gram-Positive Bacteria Route of Administration Trends in the Market for Antibiotics New Antibiotic Development Antibiotic Drug Development, Smaller Pharmaceutical Firms Growing Public/Private Partnerships Chapter 4 Market Dynamics Market Drivers Growth Driven by Antibiotics Rising Elder Population and Infection Rate Increasing Hospital-acquired Infections Improved Awareness Market Restraints Antibiotic-resistant Infections Generics Declining R&D Investment Side Effects of Antibiotics Market Opportunities Market Expansion Novel Antibacterial Agents Chapter 5 Market Breakdown, by Product Global Market for Antibiotics by Product Cell Wall Inhibitors Protein Inhibitors DNA Inhibitors Other Types of Inhibitors Chapter 6 Market Breakdown, by Route of Administration Global Market for Antibiotics by Route of Administration Oral Antibiotics Topical Antibiotics Other Routes of Administration Chapter 7 Market Breakdown, by Region Global Market for Antibiotics by Region North America Europe Asia-Pacific Latin America Middle East and Africa Chapter 8 Impact of COVID-19 on the Pharmaceutical Industry Short-term Impact Change in Demand Shift of Communication and Promotions to Remote Interactions R&D Changes Long-term Impact Delayed Approvals for Non-COVID-related Pharmaceutical Products Self-sufficiency in Pharma Pharmaceutical Industry Growth Slowdown Changes in Consumption Trends in Health-related Products Chapter 9 Clinical Developments and Pipeline Products Respiratory Tract Infections Chapter 10 Value Chain Analysis Introduction China: Center of Microbial Threat Chapter 11 Regulatory Scenario FDA and International Regulation Recent Regulatory Reforms Ketek Case Study Chapter 12 Competitive Landscape Global Company Market Share Analysis Mergers, Collaborations, Partnerships and Acquisitions Chapter 13 Company Profiles ABBOTT F. HOFFMANN-LA ROCHE AG GLAXOSMITHKLINE PLC JOHNSON & JOHNSON MERCK & CO. INC. PFIZER INC. SANOFI VIATRIS INC. Chapter 14 Appendix: Acronyms
List of Tables Summary Table A : Global Market for Antibiotics, by Product, Through 2027 Summary Table B : Global Market for Antibiotics, by Route of Administration, Through 2027 Table 1 : Major Differences, Gram-Positive and Gram-Negative Organisms Table 2 : Proportion of Resistant Strains, by WHO Region Table 3 : Global Market for Antibiotics, by Product, Through 2027 Table 4 : Global Market for Cell Wall Inhibitor, by Product, Through 2027 Table 5 : Global Market for Cell Wall Inhibitors, by Region, Through 2027 Table 6 : Global Market for Protein Inhibitors, by Product, Through 2027 Table 7 : Global Market for Protein Inhibitors, by Region, Through 2025 Table 8 : Global Market for DNA Inhibitors, by Product, Through 2027 Table 9 : Global Market for DNA Inhibitors, by Region, Through 2027 Table 10 : Global Market for Other Types of Inhibitors, by Region, Through 2027 Table 11 : Global Market for Antibiotics, by Route of Administration, Through 2027 Table 12 : Global Market for Antibiotics, by Region, Through 2027 Table 13 : North American Market for Antibiotics, by Product, Through 2027 Table 14 : North American Market for Antibiotics, by Country, Through 2027 Table 15 : European Market for Antibiotics, by Product, Through 2025 Table 16 : European Market for Antibiotics, by Country, Through 2025 Table 17 : Asia-Pacific Market for Antibiotics, by Product, Through 2027 Table 18 : Asia-Pacific Market for Antibiotics, by Country, Through 2027 Table 19 : Latin American Market for Antibiotics, by Product, Through 2027 Table 20 : Latin American Market for Antibiotics, by Country, Through 2025 Table 21 : Middle Eastern and African Market for Antibiotics, by Product, Through 2027 Table 22 : Middle Eastern and African Market for Antibiotics, by Country, Through 2027 Table 23 : Antibiotics and Combinations in Global Clinical Development, Recent Approvals,2023 Table 24 : FDA-approved Antibacterial Drugs, 2018 Table 25 : FDA-Approved Antibacterial Drugs, 2019 Table 26 : Abbott: Antibiotics Product Portfolio Table 27 : F. Hoffmann-La Roche AG: Antibiotics Product Portfolio Table 28 : GlaxoSmithKline Plc: Antibiotics Product Portfolio Table 29 : Johnson & Johnson: Antibiotics Product Portfolio Table 30 : Merck & Co. Inc.: Antibiotics Product Portfolio Table 31 : Merck & Co. Inc.: Antibiotic Drug Overview Table 32 : Pfizer Inc.: Antibiotics Product Portfolio Table 33 : Sanofi: Antibiotics Product Portfolio Table 34 : Sanofi S.A.: Antibiotic Drugs Overview Table 35 : Vitaris Inc.: Antibiotics Product Portfolio Table 36 : Acronyms Used in this Report